相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes
A. Brett Hauber et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes
James J. Chamberlain et al.
ANNALS OF INTERNAL MEDICINE (2016)
Medication Adherence Affects Risk of New Diabetes Complications: A Cohort Study
Scot H. Simpson et al.
ANNALS OF PHARMACOTHERAPY (2016)
Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study
Robert R. Henry et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2016)
Perceptions and experiences of taking oral medications for the treatment of Type 2 diabetes mellitus: a systematic review and meta-synthesis of qualitative studies
J. McSharry et al.
DIABETIC MEDICINE (2016)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2016 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2016)
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants
Bin Zhou et al.
LANCET (2016)
Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
Heather L. Gelhorn et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database
Kristina Secnik Boye et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
William H. Polonsky et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study
Manuj Sharma et al.
BMJ OPEN (2016)
A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany
Christine Poulos et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
Qing Qiao et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2016)
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
William B. Saunders et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY (2016)
Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment
Christine Poulos et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2016)
What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences
Axel Muehlbacher et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2016)
Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study
Erin K. Buysman et al.
ADVANCES IN THERAPY (2015)
Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany - a retrospective cohort and case control study in claims data of a large statutory health insurance
Michael W. J. Boehme et al.
BMC PUBLIC HEALTH (2015)
Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients
Ronan T. Grimes et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice
Curtis Triplitt et al.
DIABETES EDUCATOR (2015)
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK
Heather L. Gelhorn et al.
PATIENT PREFERENCE AND ADHERENCE (2015)
A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
A. Brett Hauber et al.
DIABETES THERAPY (2015)
A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
A. Brett Hauber et al.
DIABETES THERAPY (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
GLP-1 receptor agonists: a review of head-to-head clinical studies
Jennifer M. Trujillo et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2015)
Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
Stephen S. Johnston et al.
ADVANCES IN THERAPY (2014)
Global estimates of diabetes prevalence for 2013 and projections for 2035
L. Guariguata et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Prevalence and Incidence of Diabetes in Stockholm County 1990-2010
Tomas Andersson et al.
PLOS ONE (2014)
GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Jennifer M. Trujillo et al.
PHARMACOTHERAPY (2014)
The association between the measurement of adherence to anti-diabetes medicine and the HbA1c
Sheila A. Doggrell et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2014)
Predictors of medication adherence in patients with type 2 diabetes mellitus
Suellen M. Curkendall et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: Patient preferences
A.F. Mohamed et al.
DIABETES & METABOLISM (2013)
A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
D. A. Scott et al.
DIABETES OBESITY & METABOLISM (2013)
Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK
H. L. Gelhorn et al.
DIABETES OBESITY & METABOLISM (2013)
Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force
F. Reed Johnson et al.
VALUE IN HEALTH (2013)
A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis
S. L. Shingler et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Adherence to Therapies in Patients with Type 2 Diabetes
Luis-Emilio Garcia-Perez et al.
DIABETES THERAPY (2013)
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2012)
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials
Faramarz Ismail-Beigi et al.
ANNALS OF INTERNAL MEDICINE (2011)
A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes
Carl Asche et al.
CLINICAL THERAPEUTICS (2011)
Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment
Mette Bogelund et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
John F. P. Bridges et al.
VALUE IN HEALTH (2011)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
Kazuya Iwamoto et al.
ENDOCRINE JOURNAL (2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Quick and easy choice sets: Constructing optimal and nearly optimal stated choice experiments
DJ Street et al.
INTERNATIONAL JOURNAL OF RESEARCH IN MARKETING (2005)
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
B Elbrond et al.
DIABETES CARE (2002)
分享论文
